Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 45.0% in July

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 62,455 shares, a decline of 45.0% from the June 30th total of 113,463 shares. Based on an average trading volume of 48,069 shares, the short-interest ratio is presently 1.3 days. Currently, 12.5% of the company’s shares are sold short.

Sunshine Biopharma Stock Performance

Shares of SBFM stock opened at $1.23 on Friday. The company has a market capitalization of $615,000.00, a P/E ratio of -0.10 and a beta of 1.13. Sunshine Biopharma has a 52 week low of $1.10 and a 52 week high of $24.30. The company’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $7.72.

Sunshine Biopharma (NASDAQ:SBFM) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($1.60) by $1.35. Sunshine Biopharma had a negative net margin of 18.45% and a negative return on equity of 27.75%. The business had revenue of $8.09 million for the quarter, compared to analysts’ expectations of $9.20 million. Analysts forecast that Sunshine Biopharma will post -6.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Friday, July 17th. Zacks Research raised shares of Sunshine Biopharma to a “hold” rating in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sunshine Biopharma currently has an average rating of “Hold” and an average target price of $70.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SBFM. Two Sigma Investments LP bought a new position in shares of Sunshine Biopharma in the 3rd quarter valued at about $32,000. Virtu Financial LLC acquired a new stake in shares of Sunshine Biopharma in the 4th quarter valued at approximately $29,000. Finally, Citadel Advisors LLC increased its holdings in Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after buying an additional 14,656 shares during the last quarter. Institutional investors own 41.98% of the company’s stock.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.